A Review of Daclatasvir Drug-Drug Interactions - Wikidata - awgldk - TriplyDB

A Review of Daclatasvir Drug-Drug Interactions

A Review of Daclatasvir Drug-Drug Interactions

http://www.wikidata.org/entity/Q28068712

about

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.Era of direct acting anti-viral agents for the treatment of hepatitis C

P2860

Q47278098-4BA33677-B431-4923-81D3-3322454C46A2 Q58603882-4F5F293F-7633-49C3-9B51-26CFFF85A7FB

P2860

A Review of Daclatasvir Drug-Drug Interactions

http://www.wikidata.org/entity/Q28068712

description

2016 nî lūn-bûn

@nan

2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

A Review of Daclatasvir Drug-Drug Interactions

@ast

A Review of Daclatasvir Drug-Drug Interactions

@en

A Review of Daclatasvir Drug-Drug Interactions

@nl

type

label

A Review of Daclatasvir Drug-Drug Interactions

@ast

A Review of Daclatasvir Drug-Drug Interactions

@en

A Review of Daclatasvir Drug-Drug Interactions

@nl

prefLabel

A Review of Daclatasvir Drug-Drug Interactions

@ast

A Review of Daclatasvir Drug-Drug Interactions

@en

A Review of Daclatasvir Drug-Drug Interactions

@nl

P1433

Q28068712-4711FD11-EBB4-46A4-BFFE-20AB0CF2D27B

P1476

Q28068712-8ACCF83B-C775-4F5C-9F44-EE45E98C4B10

P2093

Q28068712-25CFD003-512F-48C5-AF0E-D004998BEF98

Q28068712-3D073CBD-6337-43FB-8097-3B046FB2F975

Q28068712-50FD6D92-097C-406E-BA0D-6CBE6AD932A9

Q28068712-59990AB1-F27C-4FFD-9B27-027D8355A9D8

Q28068712-7F83CF13-655D-43CD-9DAB-F014A600BA2F

Q28068712-943958EB-B232-4324-8C18-3CA4C2A4B1EB

Q28068712-9BB48DC6-3C91-495F-93D1-A2DD69690C3A

Q28068712-A0627F32-8A1F-4D71-A28F-60EF3C1BE21E

P2860

Q28068712-10FFFBA0-BF49-4103-B474-EE09A7F0DCBA

Q28068712-12A6EA85-6070-4BCD-8881-32BD74C8A630

Q28068712-2E3D6EA5-83EC-45C4-80B1-E3EB36E2903C

Q28068712-5402A88F-B95A-4B2E-9EB8-722FCEDB7811

Q28068712-5BF1B0B5-62BD-4270-9611-F83A717CDDC6

Q28068712-7463190D-C646-4536-8230-4BC9B533EC06

Q28068712-7F2884B5-6965-4380-B4E9-CB7881A5B653

Q28068712-7F79A76A-62FE-4B5E-8B38-7689720CEBDE

Q28068712-8FDBC4AB-E0E0-4D2A-B58E-F60CEBBEE863

Q28068712-91351AC4-66B0-4177-901D-3D4018B981D1

P2888

Q28068712-47290083-D487-447A-BB3F-91A090EB6642

P304

Q28068712-E3CDBAA7-783B-4205-B069-1242B546FE12

P31

Q28068712-2462AF5C-EEC3-4E3C-A8C9-BF1E5B766F7B

Q28068712-3419126A-1CF3-4E6E-BDDB-CA6A9F0E78F7

P3181

Q28068712-31244D88-31BB-43C4-9B60-A04DB9324939

P356

Q28068712-D724CB01-CCD9-4146-AC3B-B7A96A88D765

P407

Q28068712-257E07E5-10BC-487B-9462-74DCE35F42B2

P433

Q28068712-EE65A8A9-9B07-4BFA-B12B-FD69EFCF1736

P478

Q28068712-A64E273A-FDC3-4005-A29F-A49B40CB459E

P577

Q28068712-54C035A4-2AC2-4F61-83C2-6EA83C8A1C03

Q28068712-EA80235C-5DF7-4172-9488-B27365C86AC3

P6179

Q28068712-E5E6C76E-3D6C-43AF-96B6-9148D12008B6

P698

Q28068712-3285B702-BB60-49BE-85D1-324F953AE232

P921

Q28068712-AB1FF7DD-11EB-4169-87DF-D0DDE6B00192

Q28068712-E867DE4B-75BA-43B8-B537-41A3734592F8

P932

Q28068712-424F8DE0-5022-4ABF-895B-F5BE595354B2

P3181

P356

S12325-016-0407-5

P1433

Advances in Therapy

P1476

A Review of Daclatasvir Drug-Drug Interactions

@en

P2093

Hamza Kandoussi

http://www.w3.org/2001/XMLSchema#string

Marc Bifano

http://www.w3.org/2001/XMLSchema#string

Reena Wang

http://www.w3.org/2001/XMLSchema#string

Richard Bertz

http://www.w3.org/2001/XMLSchema#string

Shu-Pang Huang

http://www.w3.org/2001/XMLSchema#string

Timothy Eley

http://www.w3.org/2001/XMLSchema#string

Tushar Garimella

http://www.w3.org/2001/XMLSchema#string

Xiaoli You

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews

Drug-drug interactions during antiviral therapy for chronic hepatitis C

Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins.

Major depressive disorder in hepatitis C: an open-label trial of escitalopram

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.

Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir

P2888

s12325-016-0407-5

P304

1867-1884

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3365913

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S12325-016-0407-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030979745

http://www.w3.org/2001/XMLSchema#string

P698

27664109

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

physiological phenomena

P932

5083780

http://www.w3.org/2001/XMLSchema#string